查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026855

小分子免疫調節劑市場預測至2034年：按產品、應用、最終用戶和地區分類的全球分析

Small Molecule Immunomodulators Market Forecasts to 2034 - Global Analysis By Product, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球小分子免疫調節劑市場規模將達到 2,141.5 億美元，在預測期內以 8.2% 的複合年成長率成長，到 2034 年將達到 4022.9 億美元。

小分子免疫調節劑是分子量較小的化合物，能夠調節免疫系統。這些化合物在調節免疫反應中發揮著至關重要的作用，它們可以根據需要增強或抑制免疫反應。由於小分子免疫調節劑具有治療多種疾病的潛在用途，包括自體免疫疾病、發炎性疾病和某些癌症，它們可以透過精細調節免疫系統的活性來產生治療效果，因此在免疫治療領域中得到了廣泛的研究。

根據美國多發性硬化症協會 2020 年 9 月發布的報告，全球有 280 萬人患有多發性硬化症，其中超過 100 萬人居住在美國。

免疫疾病發生率增加

免疫疾病盛行率的激增是推動小分子免疫調節劑發展的主要動力。隨著自體免疫疾病和其他免疫疾病的日益普遍，對創新治療方法的需求也隨之成長。旨在從分子層面調節免疫反應的小分子免疫調節劑因其在治療這些疾病方面的潛力而備受關注。因此，免疫疾病發生率的上升正在推動相關研究、開發和市場擴張。

副作用和安全問題

小分子免疫調節劑可能產生胃腸道失調、皮膚反應和免疫抑制等副作用。安全性問題包括對免疫功能的長期影響以及機會性性行為感染的風險。此外，藥物交互作用和個體反應差異也是挑戰。另外，這些免疫調節劑的長期影響仍在研究中，人們對可能出現意外結果的擔憂日益加劇，這進一步阻礙了市場需求。

藥物研發進展

標靶治療、個人化醫療和新型小分子化合物等創新技術在調節免疫系統方面展現出令人矚目的成果。這些進展不僅提高了治療效果，而且最大限度地減少了副作用。免疫調節領域藥物研發的不斷發展，為市場成長創造了有利環境，並為透過精準有效的干涉措施應對各種疾病和病症提供了新的途徑。

與學名藥的競爭

主要免疫調節藥物專利的到期導致小分子免疫調節藥物市場出現激烈的非專利競爭。專利到期後，學名藥生產商可以進入市場，提供比原廠藥更經濟實惠的替代藥物。這種競爭加劇為患者提供了更多經濟有效的選擇。然而，製藥公司之間日益激烈的競爭可能會降低原廠藥生產商的利潤率，從而可能阻礙市場擴張。

新冠疫情的感染疾病

新冠疫情對小分子免疫調節藥物市場產生了重大影響。人們對增強免疫反應和治療發炎性疾病的日益關注推動了對免疫調節劑的需求。然而，藥品供應鏈中斷、臨床試驗延誤以及經濟不確定性都對市場成長造成了影響。疫情凸顯了免疫調節藥物研發的重要性，但生產和分銷方面的挑戰限制了市場擴張。整體而言，這場持續的全球健康危機為市場帶來了機會和挑戰。

在預測期內，心臟外科領域預計將擁有最大的市場規模。

由於心臟外科手術的精準性和有效性，該領域正蓄勢待發，有望顯著發展。小分子免疫調節劑在心臟手術期間調節免疫反應、降低發炎反應、最佳化身體對手術的耐受性方面發揮著至關重要的作用。這有助於最大限度地減少術後併發症，並改善患者的整體預後。這些免疫調節劑的精準性和標靶定向使其成為心臟外科手術領域不可或缺的輔助手段。

在預測期內，醫院和診所領域預計將呈現最高的複合年成長率。

在預測期內，醫院和診所領域預計將呈現最高的複合年成長率。在醫院和診所中，小分子免疫調節劑市場透過調節免疫反應，在治療多種疾病方面發揮著至關重要的作用。這些藥物用於治療自體免疫疾病、癌症和發炎性疾病。它們有助於改善患者預後，同時最大限度地降低副作用風險。其療效和安全性是推動該領域成長的主要因素。

市佔率最大的地區：

由於自體免疫疾病病例不斷增加，預計亞太地區將在預測期內佔據最大的市場佔有率。人們對這些疾病的認知不斷提高，加上醫療保健投入的增加，正在推動市場擴張。此外，該地區人口老化和生活方式的改變也加劇了自體免疫疾病的發生。隨著製藥公司致力於研發和商業化創新免疫調節藥物，隨著免疫挑戰日益嚴峻，對有效治療方法的需求不斷成長，預計亞太市場將迎來顯著成長。

複合年成長率最高的地區：

預計北美地區在預測期內將呈現最高的複合年成長率，這主要得益於門診手術的日益普及以及對具成本效益醫療服務的日益重視。自體免疫疾病盛行率的上升和人口老化正在推動對先進免疫調節療法的需求。該地區完善的醫療基礎設施和持續的研發活動也促進了市場擴張。主要企業正加大對新藥研發的投資，加劇了市場競爭。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球小分子免疫調節劑市場：依產品分類

  • 免疫抑制劑
    • Calcineurin抑制劑
    • 糖皮質激素
    • mTOR抑制劑
  • 免疫促效劑
    • 白細胞介素
    • 干擾素
  • 鞘氨醇-1-磷酸（S1P）受體調變器
  • Janus激酶（JAK）抑制劑
  • 其他產品

第6章 全球小分子免疫調節劑市場：依應用分類

  • 胸部
  • 眼科
  • 冒號
  • 心臟外科手術
  • 神經外科
  • 整形外科
  • 婦科
  • 其他用途

第7章 全球小分子免疫調節劑市場：依最終用戶分類

  • 醫院和診所
  • 製藥和生物技術公司
  • 研究和學術機構
  • 門診手術中心
  • 居家醫療環境
  • 其他最終用戶

第8章 全球小分子免疫調節劑市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Boston Scientific Corporation
  • Medline Industries
  • Molnlycke Health Care
  • Cardinal Health Inc
  • Owens & Minor, Inc.
  • B. Braun Melsungen AG
  • Teleflex Incorporated
  • Smith & Nephew Plc
  • Thermo Fisher Scientific Inc.
  • Halyard Health Inc
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Limited
  • Novartis AG
  • Odyssey Therapeutics Inc
Product Code: SMRC24632

According to Stratistics MRC, the Global Small Molecule Immunomodulators Market is accounted for $214.15 billion in 2026 and is expected to reach $402.29 billion by 2034 growing at a CAGR of 8.2% during the forecast period. Small molecule immunomodulators are compounds with low molecular weight that can regulate the immune system. These compounds play a crucial role in modulating immune responses, either enhancing or suppressing them as needed. Small molecule immunomodulators are extensively studied in the field of immunotherapy for their potential in treating various diseases, including autoimmune disorders, inflammatory conditions, and certain cancers, by fine-tuning the immune system's activity for therapeutic benefits.

According to a report published by the National Multiple Sclerosis Society in September 2020, there are 2.8 million people worldwide who have multiple sclerosis, and more than 1 million reside in the United States alone.

Market Dynamics:

Driver:

Rising incidence of immunological disorders

The escalating prevalence of immunological disorders is a key catalyst of the small molecule immunomodulators. As autoimmune diseases and other immunological disorders become more widespread, there is an increasing demand for innovative therapeutic solutions. Small molecule immunomodulators, designed to modulate the immune response at a molecular level, are gaining prominence for their potential in managing these conditions. This rising incidence of immunological disorders is thereby driving research, development, and market expansion.

Restraint:

Side effects and safety concerns

The small molecule immunomodulators may entail side effects such as gastrointestinal issues, skin reactions, and immune suppression. Safety concerns include potential long-term impacts on immune function and the risk of opportunistic infections. Additionally, drug interactions and individual variability in response pose challenges. Moreover, the long-term effects of these immunomodulators remain under scrutiny, raising concerns about potential unforeseen consequences which further hinder the market demand.

Opportunity:

Advancements in drug development

Innovations such as targeted therapies, personalized medicine, and novel small molecule compounds have shown promising results in modulating the immune system. These advancements not only enhance treatment efficacy but also contribute to minimizing adverse effects. The evolving landscape of drug development in immunomodulation creates a favourable environment for market growth, offering new avenues for addressing various diseases and disorders through precise and effective interventions.

Threat:

Generic competition

The small molecule immunomodulators witnesses robust generic competition due to the expiration of patents for key immunomodulatory drugs. As patents expire, generic pharmaceutical companies can enter the market, offering more affordable alternatives to the original branded drugs. This increased competition promotes cost-effective options for patients. This intensified competition among pharmaceutical companies, potentially leads to reduced profit margins for innovator companies thereby hampering the market expansion.

Covid-19 Impact

The covid-19 pandemic has significantly impacted the small molecule immunomodulators Market. The increased focus on enhancing immune responses and treating inflammatory conditions has driven demand for immunomodulators. However, disruptions in the pharmaceutical supply chain, delayed clinical trials, and economic uncertainties have affected market growth. The pandemic has underscored the importance of research and development in immunomodulatory drugs, but challenges in manufacturing and distribution have tempered market expansion. Overall, the market has experienced a mixed impact with both opportunities and challenges arising from the ongoing global health crisis.

The cardiac surgery segment is expected to be the largest during the forecast period

The cardiac surgery segment is estimated to have a lucrative growth, due to its accuracy and efficacy. Small molecule immunomodulators play a crucial role in modulating the immune response during cardiac surgery, mitigating inflammatory reactions and optimizing the body's tolerance to the procedure. It minimizes postoperative complications and enhances overall patient outcomes. The precision and targeted nature of these immunomodulators makes them valuable adjuncts in the field of cardiac surgery.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

The hospitals & clinics segment is anticipated to witness the highest CAGR growth during the forecast period. In hospitals and clinics, the Small Molecule Immunomodulators market plays a pivotal role in addressing diverse medical conditions by modulating immune responses. These pharmaceuticals are administered to manage autoimmune disorders, cancer, and inflammatory diseases. They contribute positive patient outcomes while minimizing risks associated with adverse reactions. Its efficacy and safety factors boost the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to escalating cases of immunological disorders. The rising awareness of these conditions, coupled with increasing healthcare investments, is fostering market expansion. Moreover, the region's growing geriatric population and changing lifestyles contribute to the surge in autoimmune diseases. As pharmaceutical companies focus on developing and commercializing innovative immunomodulatory drugs, the Asia-Pacific market is poised for significant advancement, driven by the pressing need for effective treatments in the face of rising immunological challenges.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increased adoption of outpatient surgical procedures and the growing emphasis on cost-effective healthcare services. Increased prevalence of autoimmune diseases and a rising aging population are driving demand for advanced immunomodulatory therapies. The region's well-established healthcare infrastructure and ongoing research initiatives contribute to market expansion. Key players are investing in novel drug development, bolstering the market's competitive landscape.

Key players in the market

Some of the key players profiled in the Small Molecule Immunomodulators Market include Boston Scientific Corporation, Medline Industries, Molnlycke Health Care, Cardinal Health Inc, Owens & Minor, Inc., B. Braun Melsungen AG, Teleflex Incorporated, Smith & Nephew Plc, Thermo Fisher Scientific Inc., Halyard Health Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Limited, Novartis AG and Odyssey Therapeutics Inc.

Key Developments:

In December 2022, Medline Industries, as part of the European Commission's rescEU program, donated 59 pallets containing 14 tons of medical supplies to Ukraine. The contribution included essential items like delivery kits, oxygen therapy equipment, scrub suits, and scalpels & sutures, aiding healthcare efforts in the country.

In October 2022, Odyssey Therapeutics Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, announced a $168 million Series B financing. The proceeds will enable Odyssey to advance its portfolio of precision immunomodulators and oncology medicines in support of its mission of developing innovative medicines to treat serious human diseases.

Products Covered:

  • Immunosuppressants
  • Immunostimulants
  • Sphingosine-1-Phosphate (S1P) Receptor Modulators
  • Janus Kinase (JAK) Inhibitors
  • Other Products

Applications Covered:

  • Thoracic
  • Ophthalmology
  • Colorectal
  • Cardiac Surgery
  • Neurosurgery
  • Orthopedic
  • Gynecology
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Institutes
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Small Molecule Immunomodulators Market, By Product

  • 5.1 Introduction
  • 5.2 Immunosuppressants
    • 5.2.1 Calcineurin Inhibitors
    • 5.2.2 Glucocorticoids
    • 5.2.3 mTOR Inhibitors
  • 5.3 Immunostimulants
    • 5.3.1 Interleukins
    • 5.3.2 Interferons
  • 5.4 Sphingosine-1-Phosphate (S1P) Receptor Modulators
  • 5.5 Janus Kinase (JAK) Inhibitors
  • 5.6 Other Products

6 Global Small Molecule Immunomodulators Market, By Application

  • 6.1 Introduction
  • 6.2 Thoracic
  • 6.3 Ophthalmology
  • 6.4 Colorectal
  • 6.5 Cardiac Surgery
  • 6.6 Neurosurgery
  • 6.7 Orthopedic
  • 6.8 Gynecology
  • 6.9 Other Applications

7 Global Small Molecule Immunomodulators Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals & Clinics
  • 7.3 Pharmaceutical & Biotechnology Companies
  • 7.4 Research & Academic Institutes
  • 7.5 Ambulatory Surgical Centers
  • 7.6 Homecare Settings
  • 7.7 Other End Users

8 Global Small Molecule Immunomodulators Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Boston Scientific Corporation
  • 10.2 Medline Industries
  • 10.3 Molnlycke Health Care
  • 10.4 Cardinal Health Inc
  • 10.5 Owens & Minor, Inc.
  • 10.6 B. Braun Melsungen AG
  • 10.7 Teleflex Incorporated
  • 10.8 Smith & Nephew Plc
  • 10.9 Thermo Fisher Scientific Inc.
  • 10.10 Halyard Health Inc
  • 10.11 Eli Lilly and Company
  • 10.12 Teva Pharmaceutical Industries Limited
  • 10.13 Novartis AG
  • 10.14 Odyssey Therapeutics Inc

List of Tables

  • Table 1 Global Small Molecule Immunomodulators Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Small Molecule Immunomodulators Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Small Molecule Immunomodulators Market Outlook, By Immunosuppressants (2023-2034) ($MN)
  • Table 4 Global Small Molecule Immunomodulators Market Outlook, By Calcineurin Inhibitors (2023-2034) ($MN)
  • Table 5 Global Small Molecule Immunomodulators Market Outlook, By Glucocorticoids (2023-2034) ($MN)
  • Table 6 Global Small Molecule Immunomodulators Market Outlook, By mTOR Inhibitors (2023-2034) ($MN)
  • Table 7 Global Small Molecule Immunomodulators Market Outlook, By Immunostimulants (2023-2034) ($MN)
  • Table 8 Global Small Molecule Immunomodulators Market Outlook, By Interleukins (2023-2034) ($MN)
  • Table 9 Global Small Molecule Immunomodulators Market Outlook, By Interferons (2023-2034) ($MN)
  • Table 10 Global Small Molecule Immunomodulators Market Outlook, By Sphingosine-1-Phosphate (S1P) Receptor Modulators (2023-2034) ($MN)
  • Table 11 Global Small Molecule Immunomodulators Market Outlook, By Janus Kinase (JAK) Inhibitors (2023-2034) ($MN)
  • Table 12 Global Small Molecule Immunomodulators Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 13 Global Small Molecule Immunomodulators Market Outlook, By Application (2023-2034) ($MN)
  • Table 14 Global Small Molecule Immunomodulators Market Outlook, By Thoracic (2023-2034) ($MN)
  • Table 15 Global Small Molecule Immunomodulators Market Outlook, By Ophthalmology (2023-2034) ($MN)
  • Table 16 Global Small Molecule Immunomodulators Market Outlook, By Colorectal (2023-2034) ($MN)
  • Table 17 Global Small Molecule Immunomodulators Market Outlook, By Cardiac Surgery (2023-2034) ($MN)
  • Table 18 Global Small Molecule Immunomodulators Market Outlook, By Neurosurgery (2023-2034) ($MN)
  • Table 19 Global Small Molecule Immunomodulators Market Outlook, By Orthopedic (2023-2034) ($MN)
  • Table 20 Global Small Molecule Immunomodulators Market Outlook, By Gynecology (2023-2034) ($MN)
  • Table 21 Global Small Molecule Immunomodulators Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 22 Global Small Molecule Immunomodulators Market Outlook, By End User (2023-2034) ($MN)
  • Table 23 Global Small Molecule Immunomodulators Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 24 Global Small Molecule Immunomodulators Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 25 Global Small Molecule Immunomodulators Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 26 Global Small Molecule Immunomodulators Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
  • Table 27 Global Small Molecule Immunomodulators Market Outlook, By Homecare Settings (2023-2034) ($MN)
  • Table 28 Global Small Molecule Immunomodulators Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.